Researchers at ASCO presented data on the genomic differences in tumors based on IHC and imaging, between racial groups, and ...

The patient advocacy organization wants to advance three disease-modifying drug candidates into clinical trials by 2028.

The firm will test BBO-8520's activity alone and with Keytruda in NSCLC patients who've received a first-generation KRAS G12C inhibitor.

Relay further disclosed a program in vascular malformations and an NRAS-selective inhibitor that it is planning to bring into clinical development in 2025.

The firm will use the funds to prepare for the commercialization of its lead radiopharmaceutical and grow its radioisotope manufacturing capabilities.

After three years of follow-up, mRNA-4157 plus Keytruda led to a 49 percent reduction in the risk of disease recurrence or ...

The immunotherapy led to durable responses, with 24 patients experiencing a complete response for at least one year.

NEW YORK – Five children in China born with severe deafness have exhibited signs of restored hearing after receiving a gene ...

In a draft guidance, the agency outlined how the well-understood and reproducible components of genetic medicines could ...

The organizations will explore opportunities to conduct preclinical and clinical trials in the UAE and leverage the UAE's genome program.

The study showed a numeric but non-statistically significant association between a high-risk genotype and increased rates of taxane-induced peripheral neuropathy.

Data presented at ASCO found that only a dozen out of 800 patients with NTRK-altered advanced solid tumors got Vitrakvi or Rozlytrek over a two-year period.